FTX Slush Fund Bankrolled Fake Studies To Hide Covid Therapeutics
FTX funded studies through TOGETHER Trial falsely claiming hydroxychloroquine, ivermectin weren't effective Covid treatments.
Clinical trials that found therapeutic medications ivermectin and hydroxychloroquine were ineffective Covid treatments were funded by defunct crypto exchange FTX.
Amid the Covid pandemic, the FTX Foundation, helmed by now-infamous FTX CEO Sam Bankman-Fried, bankrolled a clinical trial study group known as Together.
Together ran trials that purportedly aimed “to identify effective repurposed therapies to prevent the disease progression of COVID-19.”
“Can we use existing medications to treat people with early diagnosed COVID-19?” the Together group was supposedly tasked with figuring out.
ogether investigated several medications which were being touted as possible low-cost Covid remedies, among them anti-parasitic drug ivermectin and Hydroxychloroquine.
One such large-scale multi-author study published by Together in the New England Journal of Medicine looked at whether ivermectin could be effective at preventing Covid-19 hospitalization.
The study’s conclusion claimed: “Treatment with ivermectin did not result in a lower incidence of medical admission to a hospital due to progression of Covid-19 or of prolonged emergency department observation among outpatients with an early diagnosis of Covid-19.”
The results of Together’s ivermectin study were cited earlier this year by mainstream media outlets, such as the New York Times, as one more nail in the coffin proving the drug “does not reduce risk of Covid hospitalization.”
Discussing the study’s results in an interview with the Times, researcher Dr. David Boulware knocked the drug, saying, “There’s really no sign of any benefit.”
“Now that people can dive into the details and the data, hopefully that will steer the majority of doctors away from ivermectin towards other therapies,” Dr. Boulware told the Times.
The article also quoted Brigham and Women’s Hospital clinical director Dr. Paul Sax, saying, “At some point it will become a waste of resources to continue studying an unpromising approach.”
The Cato Institute pushed back against Together’s clinical trial over the summer, noting the study should be scrutinized to see if researchers were biased, in addition to a host of other possible study errors.
Together researchers also ran the same hit job on hydroxychloroquine, ultimately coming to the conclusion that: “In this randomized clinical trial, neither hydroxychloroquine nor lopinavir-ritonavir showed any significant benefit for decreasing COVID-19–associated hospitalization or other secondary clinical outcomes.”
A chart of investigated interventions provided by Together shows studies into the possible efficacy of hydroxychloroquine and ivermectin were “Stopped early for futility.”
Both hydroxychloroquine and ivermectin were promoted as inexpensive but effective alternative therapeutics that successfully treated Covid-19 infections for many physicians during early treatment protocols.
The FTX Foundation has also noted they invested in “next-generation coronavirus vaccines.”
As the collapse of FTX continues to unfold, a wider picture is beginning to emerge of it not just being a Democrat slush fund, but of it being a well-funded tool to stomp out competition and pave the way for Big Pharma treatments like experimental Covid vaccines.
